Poseida Therapeutics, Inc. entered into a securities purchase agreement to issue an aggregate of 8,333,333 shares of common stock, par value $0.0001 per share at a purchase price of $3 per Share, for aggregate gross proceeds of approximately $25,000,000 with Astellas US, LLC, a Delaware limited liability company on August 4, 2023. The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the company and other obligations of the parties. The company has received $25,000,000 pursuant to exemption provided under Rule 506 of Regulation D.